India notifies tweaked trial compensation rules
This article was originally published in Scrip
Executive Summary
India has notified a slew of much awaited modifications in its clinical trial compensation regulations including clarifications concerning injury or death due to an investigational product not having its intended therapeutic effect and on the requirement of free medical management for trial-related injury.
You may also be interested in...
India's New Trial Rules Tick Right Boxes, Shed Interim Compensation Clause
India’s new trial regulations have set competitive approval timelines, provide for local trial exemption in specific instances and also drop a controversial draft clause pertaining to interim compensation payable by sponsors.
Patient Safety First But India’s ‘Interim Compensation’ Trial Rule May Spook Sponsors
India’s draft new drugs and clinical trials rules come with a prickly "no claims" clause pertaining to payment of “interim compensation” by sponsors in specific circumstances, based on an initial causality assessment by ethics committees (ECs). The new rules, at least in their current form, also give ECs near "quasi- regulatory powers" say some experts.
What’s Next At Dr Reddy’s: Biologics CDMO, Cell And Gene Therapy Push
Indian firms are getting their act together in areas like cell and gene therapy, with Dr Reddy’s aiming big and readying a facility alongside an alliance with a Chinese firm for a CAR-T therapy. The company is also doubling down in contract development and manufacturing, with an eye on opportunities in biologics.